Drug intelligence / Profile preview

FMT-c

Development stage: Unknown
Lead developer: Universidad Autónoma de Nuevo León
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

FMT-c is an oral capsule formulation of fecal microbiota transplant (FMT) developed by the Universidad Autonoma de Nuevo Leon for the treatment of recurrent Clostridioides difficile infection (rCDI). The therapy involves the transfer of a healthy donor's distal gut microbial community into the recipient's intestinal tract to restore microbial diversity and outcompete C. difficile populations. This specific formulation is delivered via oral capsules, providing a less invasive alternative to traditional delivery methods like colonoscopy or nasoduodenal tubes. In clinical studies, it has been evaluated both as a standalone therapy and in a modified form enriched with Lactobacillus to potentially enhance clinical efficacy and microbiome restoration.

Other names: Fecal Microbiota Transplant capsulesFMT capsules

Beyond the preview

Go deeper on FMT-c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FMT-c.

Explore the full profile